Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 176 entries
Sorted by: Best Match Show Resources per page
[Management of adverse events associated with molecular targeted agents].

Hinyokika kiyo. Acta urologica Japonica

Fujisawa M, Sugimura Y.
PMID: 23254791
Hinyokika Kiyo. 2012 Nov;58(11):633.

In Japan, sorafenib and sunitinib, potential molecular targeted agents for advanced renal cell carcinoma, were approved in 2008. Currently, a total of four agents, including everolimus and temsirolimus in addition to these two agents, have been introduced into clinical...

Cite
Fujisawa M, Sugimura Y. [Management of adverse events associated with molecular targeted agents]. Hinyokika Kiyo. 2012;58(11):633
Fujisawa, M., & Sugimura, Y. (2012). [Management of adverse events associated with molecular targeted agents]. Hinyokika kiyo. Acta urologica Japonica, 58(11), 633.
Fujisawa, Masato, and Sugimura, Yoshiki. "[Management of adverse events associated with molecular targeted agents]." Hinyokika kiyo. Acta urologica Japonica vol. 58,11 (2012): 633.
Fujisawa M, Sugimura Y. [Management of adverse events associated with molecular targeted agents]. Hinyokika Kiyo. 2012 Nov;58(11):633. Japanese. PMID: 23254791.
Copy Download .nbib Format: NLM
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists.

Critical reviews in oncology/hematology

Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, Cohen A, Soria JC.
PMID: 21330149
Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79. doi: 10.1016/j.critrevonc.2011.01.009. Epub 2011 Feb 16.

Molecular targeted therapies (MTTs) have become a major component of modern management of various hematological and solid malignancies. However, some MTTs have been associated with cardiotoxicity. MTT-induced cardiovascular side effects include left ventricular systolic dysfunction, heart failure, conduction abnormalities,...

Cite
Ederhy S, Izzedine H, Massard C, et al. Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 2011;80(3):369-79doi: 10.1016/j.critrevonc.2011.01.009.
Ederhy, S., Izzedine, H., Massard, C., Dufaitre, G., Spano, J. P., Milano, G., Meuleman, C., Besse, B., Boccara, F., Kahyat, D., Cohen, A., & Soria, J. C. (2011). Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Critical reviews in oncology/hematology, 80(3), 369-79. https://doi.org/10.1016/j.critrevonc.2011.01.009
Ederhy, Stephane, et al. "Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists." Critical reviews in oncology/hematology vol. 80,3 (2011): 369-79. doi: https://doi.org/10.1016/j.critrevonc.2011.01.009
Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, Cohen A, Soria JC. Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79. doi: 10.1016/j.critrevonc.2011.01.009. Epub 2011 Feb 16. PMID: 21330149.
Copy Download .nbib Format: NLM
[The brand new trend of colorectal carcinoma pathology].

Nihon rinsho. Japanese journal of clinical medicine

Tomita S, Yamauchi M, Ichikawa K, Mitomi H, Fujimori T.
PMID: 24597350
Nihon Rinsho. 2014 Jan;72(1):63-70.

Japanese classification of colorectal carcinoma continues to develop several decades. In 2015, the Japanese Society for Cancer of the Colon and Rectum published the eighth edition of the general rules for clinical and pathological studies on cancer of the...

Cite
Tomita S, Yamauchi M, Ichikawa K, et al. [The brand new trend of colorectal carcinoma pathology]. Nihon Rinsho. 2014;72(1):63-70
Tomita, S., Yamauchi, M., Ichikawa, K., Mitomi, H., & Fujimori, T. (2014). [The brand new trend of colorectal carcinoma pathology]. Nihon rinsho. Japanese journal of clinical medicine, 72(1), 63-70.
Tomita, Shigeki, et al. "[The brand new trend of colorectal carcinoma pathology]." Nihon rinsho. Japanese journal of clinical medicine vol. 72,1 (2014): 63-70.
Tomita S, Yamauchi M, Ichikawa K, Mitomi H, Fujimori T. [The brand new trend of colorectal carcinoma pathology]. Nihon Rinsho. 2014 Jan;72(1):63-70. Japanese. PMID: 24597350.
Copy Download .nbib Format: NLM
Bioorthogonal approach to identify unsuspected drug targets in live cells.

Angewandte Chemie (International ed. in English)

Yang KS, Budin G, Tassa C, Kister O, Weissleder R.
PMID: 23960025
Angew Chem Int Ed Engl. 2013 Sep 27;52(40):10593-7. doi: 10.1002/anie.201304096. Epub 2013 Aug 19.

A proteomics method to pull down secondary drug targets from live cells is described. The drug of interest is modified with trans-cyclooctene (TCO) and incubated with live cells. Upon cell lysis, the modified drug bound to the protein is...

Cite
Yang KS, Budin G, Tassa C, et al. Bioorthogonal approach to identify unsuspected drug targets in live cells. Angew Chem Int Ed Engl. 2013;52(40):10593-7doi: 10.1002/anie.201304096.
Yang, K. S., Budin, G., Tassa, C., Kister, O., & Weissleder, R. (2013). Bioorthogonal approach to identify unsuspected drug targets in live cells. Angewandte Chemie (International ed. in English), 52(40), 10593-7. https://doi.org/10.1002/anie.201304096
Yang, Katherine S, et al. "Bioorthogonal approach to identify unsuspected drug targets in live cells." Angewandte Chemie (International ed. in English) vol. 52,40 (2013): 10593-7. doi: https://doi.org/10.1002/anie.201304096
Yang KS, Budin G, Tassa C, Kister O, Weissleder R. Bioorthogonal approach to identify unsuspected drug targets in live cells. Angew Chem Int Ed Engl. 2013 Sep 27;52(40):10593-7. doi: 10.1002/anie.201304096. Epub 2013 Aug 19. PMID: 23960025; PMCID: PMC3856564.
Copy Download .nbib Format: NLM
Therapy of mantle cell lymphoma: new treatment options in an old disease or vice versa?.

Seminars in hematology

Dreyling M.
PMID: 21782055
Semin Hematol. 2011 Jul;48(3):145-7. doi: 10.1053/j.seminhematol.2011.06.003.

No abstract available.

Cite
Dreyling M. Therapy of mantle cell lymphoma: new treatment options in an old disease or vice versa?. Semin Hematol. 2011;48(3):145-7doi: 10.1053/j.seminhematol.2011.06.003.
Dreyling, M. (2011). Therapy of mantle cell lymphoma: new treatment options in an old disease or vice versa?. Seminars in hematology, 48(3), 145-7. https://doi.org/10.1053/j.seminhematol.2011.06.003
Dreyling, Martin. "Therapy of mantle cell lymphoma: new treatment options in an old disease or vice versa?." Seminars in hematology vol. 48,3 (2011): 145-7. doi: https://doi.org/10.1053/j.seminhematol.2011.06.003
Dreyling M. Therapy of mantle cell lymphoma: new treatment options in an old disease or vice versa?. Semin Hematol. 2011 Jul;48(3):145-7. doi: 10.1053/j.seminhematol.2011.06.003. PMID: 21782055.
Copy Download .nbib Format: NLM
Molecular targeted approaches in mantle cell lymphoma.

Seminars in hematology

Weniger MA, Wiestner A.
PMID: 21782064
Semin Hematol. 2011 Jul;48(3):214-26. doi: 10.1053/j.seminhematol.2011.05.001.

Mantle cell lymphoma (MCL) is a malignancy of mature B cells characterized by the translocation t(11;14) that leads to aberrant expression of cyclin D1. Response to first-line chemotherapy is good, but most patients relapse, resulting in a median survival...

Cite
Weniger MA, Wiestner A. Molecular targeted approaches in mantle cell lymphoma. Semin Hematol. 2011;48(3):214-26doi: 10.1053/j.seminhematol.2011.05.001.
Weniger, M. A., & Wiestner, A. (2011). Molecular targeted approaches in mantle cell lymphoma. Seminars in hematology, 48(3), 214-26. https://doi.org/10.1053/j.seminhematol.2011.05.001
Weniger, Marc A, and Wiestner, Adrian. "Molecular targeted approaches in mantle cell lymphoma." Seminars in hematology vol. 48,3 (2011): 214-26. doi: https://doi.org/10.1053/j.seminhematol.2011.05.001
Weniger MA, Wiestner A. Molecular targeted approaches in mantle cell lymphoma. Semin Hematol. 2011 Jul;48(3):214-26. doi: 10.1053/j.seminhematol.2011.05.001. PMID: 21782064; PMCID: PMC3143377.
Copy Download .nbib Format: NLM
Putting molecular profiling to the test.

Cancer discovery

[No authors listed]
PMID: 25367966
Cancer Discov. 2014 Nov;4(11):OF4. doi: 10.1158/2159-8290.CD-NB2014-139. Epub 2014 Sep 18.

No abstract available.

Cite
Putting molecular profiling to the test. Cancer Discov. 2014;4(11):OF4doi: 10.1158/2159-8290.CD-NB2014-139.
(2014). Putting molecular profiling to the test. Cancer discovery, 4(11), OF4. https://doi.org/10.1158/2159-8290.CD-NB2014-139
"Putting molecular profiling to the test." Cancer discovery vol. 4,11 (2014): OF4. doi: https://doi.org/10.1158/2159-8290.CD-NB2014-139
Putting molecular profiling to the test. Cancer Discov. 2014 Nov;4(11):OF4. doi: 10.1158/2159-8290.CD-NB2014-139. Epub 2014 Sep 18. PMID: 25367966.
Copy Download .nbib Format: NLM
A decade of promises in personalised cancer medicine: is the honeymoon over?.

The Medical journal of Australia

Ward RL.
PMID: 24528411
Med J Aust. 2014 Feb 17;200(3):132-3. doi: 10.5694/mja14.00018.

No abstract available.

Cite
Ward RL. A decade of promises in personalised cancer medicine: is the honeymoon over?. Med J Aust. 2014;200(3):132-3doi: 10.5694/mja14.00018.
Ward, R. L. (2014). A decade of promises in personalised cancer medicine: is the honeymoon over?. The Medical journal of Australia, 200(3), 132-3. https://doi.org/10.5694/mja14.00018
Ward, Robyn L. "A decade of promises in personalised cancer medicine: is the honeymoon over?." The Medical journal of Australia vol. 200,3 (2014): 132-3. doi: https://doi.org/10.5694/mja14.00018
Ward RL. A decade of promises in personalised cancer medicine: is the honeymoon over?. Med J Aust. 2014 Feb 17;200(3):132-3. doi: 10.5694/mja14.00018. PMID: 24528411.
Copy Download .nbib Format: NLM
Displaying chemical information on a biological network using Cytoscape.

Methods in molecular biology (Clifton, N.J.)

Wallace IM, Bader GD, Giaever G, Nislow C.
PMID: 21877291
Methods Mol Biol. 2011;781:363-76. doi: 10.1007/978-1-61779-276-2_18.

Cytoscape is an open-source software package that is widely used to integrate and visualize diverse data sets in biology. This chapter explains how to use Cytoscape to integrate open-source chemical information with a biological network. By visualizing information about...

Cite
Wallace IM, Bader GD, Giaever G, et al. Displaying chemical information on a biological network using Cytoscape. Methods Mol Biol. 2011;781:363-76doi: 10.1007/978-1-61779-276-2_18.
Wallace, I. M., Bader, G. D., Giaever, G., & Nislow, C. (2011). Displaying chemical information on a biological network using Cytoscape. Methods in molecular biology (Clifton, N.J.), 781363-76. https://doi.org/10.1007/978-1-61779-276-2_18
Wallace, Iain M, et al. "Displaying chemical information on a biological network using Cytoscape." Methods in molecular biology (Clifton, N.J.) vol. 781 (2011): 363-76. doi: https://doi.org/10.1007/978-1-61779-276-2_18
Wallace IM, Bader GD, Giaever G, Nislow C. Displaying chemical information on a biological network using Cytoscape. Methods Mol Biol. 2011;781:363-76. doi: 10.1007/978-1-61779-276-2_18. PMID: 21877291.
Copy Download .nbib Format: NLM
Cost of illness in colorectal cancer: an international review.

PharmacoEconomics

Kriza C, Emmert M, Wahlster P, Niederländer C, Kolominsky-Rabas P.
PMID: 23636661
Pharmacoeconomics. 2013 Jul;31(7):577-88. doi: 10.1007/s40273-013-0055-4.

OBJECTIVES: Given the current-and increasing-pressure to limit expenditure on health care provision in many countries, a better understanding of the cost burden of colorectal cancer is needed. Cost-of-illness studies and reviews thereof can be a useful tool for analysing...

Cite
Kriza C, Emmert M, Wahlster P, et al. Cost of illness in colorectal cancer: an international review. Pharmacoeconomics. 2013;31(7):577-88doi: 10.1007/s40273-013-0055-4.
Kriza, C., Emmert, M., Wahlster, P., Niederländer, C., & Kolominsky-Rabas, P. (2013). Cost of illness in colorectal cancer: an international review. PharmacoEconomics, 31(7), 577-88. https://doi.org/10.1007/s40273-013-0055-4
Kriza, Christine, et al. "Cost of illness in colorectal cancer: an international review." PharmacoEconomics vol. 31,7 (2013): 577-88. doi: https://doi.org/10.1007/s40273-013-0055-4
Kriza C, Emmert M, Wahlster P, Niederländer C, Kolominsky-Rabas P. Cost of illness in colorectal cancer: an international review. Pharmacoeconomics. 2013 Jul;31(7):577-88. doi: 10.1007/s40273-013-0055-4. PMID: 23636661.
Copy Download .nbib Format: NLM
Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?.

Journal of oncology practice

Chan JJ, Tan TJY, Dent RA.
PMID: 29746805
J Oncol Pract. 2018 May;14(5):281-289. doi: 10.1200/JOP.18.00034.

The working immunohistochemical definition of triple-negative breast cancer (TNBC) is admittedly reductionist and has only limited usefulness for informing oncologists about therapeutic decisions beyond chemotherapy. Early molecular taxonomies of TNBC based heavily on gene expression profiling, which is not...

Cite
Chan JJ, Tan TJY, Dent RA. Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?. J Oncol Pract. 2018;14(5):281-289doi: 10.1200/JOP.18.00034.
Chan, J. J., Tan, T. J. Y., & Dent, R. A. (2018). Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?. Journal of oncology practice, 14(5), 281-289. https://doi.org/10.1200/JOP.18.00034
Chan, Jack J, et al. "Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?." Journal of oncology practice vol. 14,5 (2018): 281-289. doi: https://doi.org/10.1200/JOP.18.00034
Chan JJ, Tan TJY, Dent RA. Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?. J Oncol Pract. 2018 May;14(5):281-289. doi: 10.1200/JOP.18.00034. PMID: 29746805.
Copy Download .nbib Format: NLM
Lung cancer as a paradigm for precision oncology in solid tumours.

Virchows Archiv : an international journal of pathology

Schallenberg S, Merkelbach-Bruse S, Buettner R.
PMID: 28730537
Virchows Arch. 2017 Aug;471(2):221-233. doi: 10.1007/s00428-017-2183-2. Epub 2017 Jul 20.

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the western world. However, the combination of molecular genotyping and subsequent systematic treatment of decoded target structures is a prime example of precision oncology in solid...

Cite
Schallenberg S, Merkelbach-Bruse S, Buettner R. Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch. 2017;471(2):221-233doi: 10.1007/s00428-017-2183-2.
Schallenberg, S., Merkelbach-Bruse, S., & Buettner, R. (2017). Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Archiv : an international journal of pathology, 471(2), 221-233. https://doi.org/10.1007/s00428-017-2183-2
Schallenberg, Simon, et al. "Lung cancer as a paradigm for precision oncology in solid tumours." Virchows Archiv : an international journal of pathology vol. 471,2 (2017): 221-233. doi: https://doi.org/10.1007/s00428-017-2183-2
Schallenberg S, Merkelbach-Bruse S, Buettner R. Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch. 2017 Aug;471(2):221-233. doi: 10.1007/s00428-017-2183-2. Epub 2017 Jul 20. PMID: 28730537.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 176 entries